中药巨头，更换董事长！

Core Viewpoint - The company, Kang En Bei, has appointed Ying Xu as the new chairman of its board of directors, effective immediately, marking a significant leadership change within the organization [1][5]. Company Overview - Kang En Bei, founded in 1969, has evolved from a local pharmaceutical factory into one of the largest traditional Chinese medicine companies in Zhejiang Province and ranks among the top in China's traditional medicine industry [3][7]. - The company was listed on the Shanghai Stock Exchange in 2004 and initiated a major brand development project in 2017, which included well-known trademarks such as Kang En Bei, Qian Lie Kang, Zhen Shi Ming, and Tian Bao Ning [3][7]. Leadership Change - Ying Xu, born in 1973 and a graduate of Shenyang Pharmaceutical University, has held various leadership roles in the pharmaceutical industry, including positions at Zhejiang Yingte Pharmaceutical Co., Ltd. and Zhejiang Yingte Group Co., Ltd. [3][7]. - As of the announcement, Ying Xu does not hold any shares in Kang En Bei [3][7]. Business Transformation - Following a mixed-ownership reform in 2020, Kang En Bei transitioned from a private enterprise to a state-controlled company, with the Zhejiang Provincial State-owned Assets Supervision and Administration Commission as its actual controller [4][8]. - The company operates in multiple sectors, including traditional Chinese medicine, chemical medicine, and health consumer products, boasting over ten billion-yuan brands such as Chang Yan Ning and Qian Lie Kang [4][8]. Financial Performance - In the first three quarters of 2025, Kang En Bei reported a revenue of 4.976 billion yuan, reflecting a year-on-year growth of 1.27%, while the net profit attributable to shareholders reached 584 million yuan, up by 12.65% [5][8]. - The Chang Yan Ning series is projected to achieve sales exceeding 1.5 billion yuan in 2024, maintaining its position as the market leader in the domestic retail market for intestinal medications [4][8].